Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM. Perl AE, et al. Among authors: swider cr. Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20. Clin Cancer Res. 2009. PMID: 19843663 Clinical Trial.
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M. Tsai DE, et al. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. Clin Cancer Res. 2008. PMID: 18765556 Clinical Trial.
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
Tsai DE, Luger SM, Kemner A, Swider C, Goradia A, Tomczak E, DiPatri D, Bagg A, Nowell P, Loren AW, Perl A, Schuster S, Thompson JE, Porter D, Andreadis C, Stadtmauer EA, Goldsteini S, Ghalie R, Carroll M. Tsai DE, et al. Cancer Biol Ther. 2007 Jan;6(1):18-21. doi: 10.4161/cbt.6.1.3619. Cancer Biol Ther. 2007. PMID: 17204865 Free article.
A robust xenotransplantation model for acute myeloid leukemia.
Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G, Carroll M. Sanchez PV, et al. Among authors: swider cr. Leukemia. 2009 Nov;23(11):2109-17. doi: 10.1038/leu.2009.143. Epub 2009 Jul 23. Leukemia. 2009. PMID: 19626050 Free PMC article.
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, Dobrzanski P. Hexner EO, et al. Among authors: swider cr. Blood. 2008 Jun 15;111(12):5663-71. doi: 10.1182/blood-2007-04-083402. Epub 2007 Nov 5. Blood. 2008. PMID: 17984313 Free PMC article.
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice.
Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, Swider CR, Strzelecki AC, Cavelier C, Récher C, Mansat-De Mas V, Delabesse E, Danet-Desnoyers G, Carroll M. Sarry JE, et al. Among authors: swider cr. J Clin Invest. 2011 Jan;121(1):384-95. doi: 10.1172/JCI41495. Epub 2010 Dec 13. J Clin Invest. 2011. PMID: 21157036 Free PMC article.
15 results